Bristol Myers Squibb's Nathan Pennell explains how the MRD endpoint supports accelerated approval in multiple myeloma without changing how clinicians monitor patients.
Nathan Pennell
Advertisement
Nathan Pennell, MD, PhD, FASCO, is senior vice president, head of Hematology and Oncology Medical Affairs at Bristol Myers Squibb.
Articles by Nathan Pennell
Advertisement
Latest Updated Articles
Advertisement
Advertisement